Liquidia Corp
NASDAQ:LQDA
Liquidia Corp
Net Income (Common)
Liquidia Corp
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Liquidia Corp
NASDAQ:LQDA
|
Net Income (Common)
-$130.4m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Net Income (Common)
$14.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Net Income (Common)
-$8.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Net Income (Common)
$8B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Net Income (Common)
$17.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Net Income (Common)
$10.6B
|
CAGR 3-Years
24%
|
CAGR 5-Years
5%
|
CAGR 10-Years
16%
|
|
Liquidia Corp
Glance View
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina and currently employs 47 full-time employees. The company went IPO on 2018-07-26. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The firm is engaged in developing product candidates from its pipeline, LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. LIQ861 is an inhaled dry powder formulation of treprostinil designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies. LIQ865, has completed a Phase Ib clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic and to treat local post-operative pain.
See Also
What is Liquidia Corp's Net Income (Common)?
Net Income (Common)
-130.4m
USD
Based on the financial report for Dec 31, 2024, Liquidia Corp's Net Income (Common) amounts to -130.4m USD.
What is Liquidia Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-22%
Over the last year, the Net Income (Common) growth was -66%. The average annual Net Income (Common) growth rates for Liquidia Corp have been -56% over the past three years , -22% over the past five years .
You don't have any saved screeners yet